The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Arrowhead Pharmaceuticals Inc. (ARWR) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.27, or 0.91%, to $29.93. The Arrowhead Pharmaceuticals Inc. has recorded 27,092 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $29.66 and fluctuated between $30.69 as its day high and $29.20 as its day low. The current market capitalization of Arrowhead Pharmaceuticals Inc. is $3.22B. A total of 1.17 million shares were traded on the day, compared to an average of 983.40K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ARWR has seen 15 BUY and 23 SELL insider trades, representing the acquisition of 584,969 and the disposition of 92,230 shares. Over the last 12 months, there were 16 BUYs and 29 SELLs from insiders. Insiders purchased 587,470 shares during that period but sold 800,227.
In the most recent transaction, OLUKOTUN ADEOYE Y sold 11,350 shares of ARWR for 32.65 per share on Mar 03. After the transaction, the Director now owns 7,867 company shares. In a previous transaction on Feb 27, GIVEN DOUGLAS B sold 875 shares at 32.62 per share. ARWR shares that Director owns now total 13,000.
Among the insiders who sold shares, Waddill William D. disposed of 3,200 shares on Jan 09 at a per-share price of $30.00. This resulted in the Director holding 28,950 shares of ARWR after the transaction. In another insider transaction, O’Brien Patrick sold 15,000 shares at $37.39 per share on Jan 05. Company shares held by the COO and General Counsel now total 413,375.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ARWR in the last 3 months, the mean price target is $63.62 with high estimates of $90.00 and low estimates of $21.00. In terms of 52-week highs and lows, ARWR has a high of $51.11 and a low of $26.81.
As of this writing, ARWR has an earnings estimate of -$0.63 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of $0.16 per share and a lower estimate of -$1.09. The company reported an EPS of -$0.81 in the last quarter, which was -406.20% lower than expectations of -$0.16.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 12 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARWR is Hold with a score of 4.55. A total of 9 analysts rated the stock as Buy while 1 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.